The data is clinically supportive but does not change Teva's near-term financial outlook. Monitor for any future label expansion or competitive dynamics in the HD chorea market, but no immediate trading catalyst from this release.
TEVA drugs
TEVA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 5 $34.19entry
- T+1 · 5mo ago −2.72%α −2.95% · $33.26
- T+5 · 5mo ago +1.29%α +0.72% · $34.63
- T+20 · 4mo ago +3.22%α +1.36% · $35.29
- T+60 · 3mo ago +5.43%α +1.43% · $36.05
Price Chart
How similar events traded
Executive Summary
Teva presented real-world survey data at a medical congress showing that AUSTEDO/AUSTEDO XR treatment for Huntington's disease chorea led to patient-reported improvements in movement and quality of life, with 74% of patients reporting improvement and over 85% reporting better daily activities and social life. The data reinforces the drug's clinical value but does not provide new financial figures, regulatory decisions, or guidance changes.
Key Facts
- Data from a real-world, decentralized study on HD chorea patients treated with AUSTEDO/AUSTEDO XR presented at the Advanced Therapeutics in Movement & Related Disorders Congress (June 4-8, 2026).
- 74% of patients reported improvement in chorea movements since initiating treatment (PGIC scale).
- Over 85% of patients reported improvements in goals related to daily activities and social life.
- 77% of caregivers reported improvements in goals related to their social life and emotional wellbeing.
- No new financial data, revenue, EPS, guidance, or regulatory action was disclosed in the press release.
Financial Impact
No financial figures provided; the press release is a clinical data update without revenue or earnings implications.
Risk Factors
- No new revenue or earnings data; the press release is purely clinical and does not alter financial expectations.
- Forward-looking statements about AUSTEDO commercialization are subject to competitive and regulatory risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307494 |
Track record
61 reports on TEVA
6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 15 of 17 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
- Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers